tiprankstipranks
Trending News
More News >
Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
Hong Kong Market
Advertisement

Raily Aesthetic Medicine International Holdings Limited (2135) AI Stock Analysis

Compare
1 Followers

Top Page

HK:2135

Raily Aesthetic Medicine International Holdings Limited

(2135)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 4o)
Rating:50Neutral
Price Target:
HK$0.00
▼(-100.00% Downside)
The overall stock score of 50 reflects significant financial challenges, including declining profitability and increasing leverage. Technical analysis shows a mild upward trend, but weak momentum. Valuation is unattractive due to negative earnings and lack of dividends. These factors collectively highlight the need for strategic improvements to enhance financial health and investor appeal.

Raily Aesthetic Medicine International Holdings Limited (2135) vs. iShares MSCI Hong Kong ETF (EWH)

Raily Aesthetic Medicine International Holdings Limited Business Overview & Revenue Model

Company DescriptionRaily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services. The company operates through three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products. Its services include aesthetic surgery services, including aesthetic surgical procedures performed on various parts of the face or body; minimally invasive aesthetic services, primarily comprising aesthetic injection procedures; aesthetic dermatology services, such as various aesthetic energy-based procedures; and aesthetic medical management consulting services. The company also offers aesthetic dental services, including orthodontics, and dental implant and whitening; and trades in medical equipment. In addition, it sells surgical implants and aesthetic medical skincare products. The company owns and operates a network of four private for-profit aesthetic medical institutions in Zhejiang and Anhui Province, the People's Republic of China. It serves individual retail clients and aesthetic medical institutions. The company was founded in 2008 and is headquartered in Hangzhou, the People's Republic of China. Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
How the Company Makes MoneyRaily Aesthetic Medicine International Holdings Limited generates revenue primarily through the provision of aesthetic medical services and the sale of related products. The key revenue streams include fees charged for various aesthetic treatments such as laser therapies, injectables, and skincare procedures. The company also earns income by selling skincare products and cosmetics associated with its treatments. Strategic partnerships with cosmetic product manufacturers and distribution channels enhance its market reach and contribute to its earnings. Additionally, Raily Aesthetic Medicine may engage in training and consulting services for professionals in the aesthetic industry, further diversifying its revenue base.

Raily Aesthetic Medicine International Holdings Limited Financial Statement Overview

Summary
Raily Aesthetic Medicine International Holdings Limited faces significant financial challenges, with declining profitability and increasing leverage. The income statement shows persistent losses, while the balance sheet indicates rising debt levels. Cash flow issues further exacerbate the company's financial position, requiring strategic adjustments to improve financial health.
Income Statement
45
Neutral
The company has shown a decline in revenue growth, with a slight increase in revenue from 2023 to 2024. Gross profit margin has decreased over the years, indicating pressure on profitability. The net profit margin remains negative, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, highlighting operational challenges.
Balance Sheet
50
Neutral
The debt-to-equity ratio has increased, indicating higher leverage and potential financial risk. The return on equity is negative due to net losses, which is concerning for shareholders. However, the equity ratio remains relatively stable, suggesting a balanced asset structure.
Cash Flow
40
Negative
The company has experienced negative free cash flow, which has worsened from 2023 to 2024. The operating cash flow to net income ratio is positive, indicating some ability to generate cash from operations despite losses. However, the free cash flow to net income ratio is negative, reflecting cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue286.47M199.34M189.38M164.52M188.37M164.54M
Gross Profit108.29M71.41M71.49M66.78M69.69M80.17M
EBITDA6.86M-34.29M-6.03M3.89M-6.00M25.95M
Net Income-45.78M-59.21M-32.46M-15.91M-17.69M4.25M
Balance Sheet
Total Assets273.60M249.92M273.60M302.65M344.73M272.33M
Cash, Cash Equivalents and Short-Term Investments39.79M28.87M39.79M78.78M111.22M165.39M
Total Debt51.78M56.37M51.78M48.22M67.45M32.19M
Total Liabilities141.01M154.41M141.01M136.77M162.37M85.58M
Stockholders Equity138.12M104.13M138.12M166.08M178.22M185.87M
Cash Flow
Free Cash Flow-4.99M-38.59M-10.00M-21.13M-18.25M5.56M
Operating Cash Flow5.04M6.01M8.02M-2.27M-2.47M14.16M
Investing Cash Flow-40.00M-12.70M-26.14M558.00K-82.45M-13.34M
Financing Cash Flow-16.73M19.43M-10.48M-25.65M11.97M92.67M

Raily Aesthetic Medicine International Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.12
Price Trends
50DMA
0.12
Negative
100DMA
0.12
Positive
200DMA
0.11
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
50.28
Neutral
STOCH
67.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2135, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.28 is Neutral, neither overbought nor oversold. The STOCH value of 67.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2135.

Raily Aesthetic Medicine International Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
8.64B29.4124.18%1.42%28.53%22.34%
60
Neutral
95.47M-12.970.00%-11.68%-71.01%
56
Neutral
86.09M-25.53-80.50%-8.20%-10.39%
56
Neutral
19.76M2.4569.48%-8.48%0.00%
50
Neutral
HK$67.96M-51.07%-20.66%-77.84%
41
Neutral
10.32M-0.3517.98%14.64%-81.95%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2135
Raily Aesthetic Medicine International Holdings Limited
0.12
0.02
20.00%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
36.72
20.80
130.65%
HK:8161
MediNet Group Ltd.
0.57
0.27
90.00%
HK:8307
Medicskin Holdings Ltd.
0.22
0.04
22.22%
HK:8357
Republic Healthcare Limited
0.15
0.08
114.29%
HK:8437
RMH Holdings Limited
0.16
-0.14
-46.67%

Raily Aesthetic Medicine International Holdings Limited Corporate Events

Raily Aesthetic Medicine Reports Increased Losses in 2025 Interim Results
Aug 29, 2025

Raily Aesthetic Medicine International Holdings Limited reported its unaudited interim results for the six months ending June 30, 2025, revealing a significant decrease in revenue and an increased loss compared to the same period in 2024. The company experienced a drop in gross profit and other income, while expenses in selling, distribution, and administration also decreased. The overall loss for the period was attributed to both owners of the parent and non-controlling interests, indicating financial challenges that may impact stakeholders and the company’s market position.

Raily Aesthetic Medicine Schedules Board Meeting for Interim Results
Aug 19, 2025

Raily Aesthetic Medicine International Holdings Limited has announced a board meeting scheduled for 29 August 2025. The meeting will address the approval of the company’s unaudited interim results for the first half of 2025 and discuss potential dividend declarations, impacting the company’s financial disclosures and shareholder returns.

Raily Aesthetic Medicine Ends Contractual Arrangements Amid Strategic Shift
Aug 15, 2025

Raily Aesthetic Medicine International Holdings Limited announced the termination of its contractual arrangements with Hangzhou Beilifeier, as the latter shifts its strategic focus towards the sales of aesthetic medical equipment products. This move comes after the cessation of Hangzhou Beilifeier’s aesthetic medical services and the application for a medical device business license, removing restrictions on foreign ownership and allowing Raily to transfer equity interests and unwind previous agreements.

Raily Aesthetic Medicine Issues Profit Warning Amid Revenue Decline
Aug 8, 2025

Raily Aesthetic Medicine International Holdings Limited has issued a profit warning, reporting a significant decline in revenue and an increase in losses for the first half of 2025. The company’s revenue fell to approximately RMB85 million, down from RMB117 million in the same period in 2024, while losses attributable to the parent company increased to around RMB8 million. The decline is attributed to intense market competition and increased expenses related to share options and research and development activities. The company advises shareholders and potential investors to exercise caution as the financial results are preliminary and subject to adjustments.

Raily Aesthetic Medicine Announces Deemed Disposal of Subsidiary Equity
Jul 4, 2025

Raily Aesthetic Medicine International Holdings Limited announced a deemed disposal of equity interest in a subsidiary through an investment agreement with two investors. The transaction involves a capital injection by the investors, resulting in a significant reduction of Hangzhou Raily’s equity in the Target Company from 100% to 30%. This move is part of a strategy to reduce accumulated losses and improve the financial position of the subsidiary. The transaction is classified as a discloseable transaction under Hong Kong’s Listing Rules, requiring an announcement but not shareholder approval.

Raily Aesthetic Medicine Enhances Governance with New Nomination Committee
Jun 27, 2025

Raily Aesthetic Medicine International Holdings Limited has established a nomination committee to identify and recommend candidates for the board of directors, oversee board performance evaluations, and develop nomination guidelines. This move is expected to enhance the governance structure of the company, ensuring compliance with applicable laws and regulations, and potentially strengthening its market position by promoting diversity and independence within its board.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025